Additional Reduction in Serum Phosphorus Levels by Pulverized Lanthanum Carbonate Chewable in Hemodialysis Patients

被引:3
|
作者
Yamashita, Tetsuri [1 ]
Ogawa, Tetsuya [2 ]
Takahashi, Masaki [1 ]
Mitsuhashi, Tetsuya [2 ]
Shizuku, Junichi [3 ]
Takahashi, Naoshi [3 ]
Ohba, Takashi [3 ]
Miyajima, Sayako [3 ]
Kabaya, Takashi [3 ]
Otsuka, Kuniaki [2 ]
Nitta, Kosaku [1 ]
机构
[1] Tokyo Womens Med Univ, Kidney Ctr, Dept Med, Tokyo 1168567, Japan
[2] Tokyo Womens Med Univ, Med Ctr East, Dept Internal Med, Tokyo 1168567, Japan
[3] Minamisenju Hosp, Tokyo, Japan
关键词
Abdominal X-ray; Hemodialysis; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder; CHRONIC-RENAL-FAILURE; DIALYSIS PATIENT; DOUBLE-BLIND; PHOSPHATE; EFFICACY; CALCIUM; TOLERABILITY;
D O I
10.1111/1744-9987.12036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lanthanum carbonate (LC) is one of the relatively new phosphate binders. The general LC dosage form is a chewable pharmaceutical preparation. This investigation was targeted to subjects who do not chew LC chewable preparations adequately, for the purpose of studying the clinical efficacy of changing to pulverized prescriptions, such as changes in serum phosphorus levels (P levels). The study took place at Minamisenju Hospital in October 2011, with 41 subjects on maintenance hemodialysis. We pulverized all of the LC chewable medicines of the LC insufficient mastication group (non-chewing: NC group, n=18) using a crusher, and changed them to pulverized prescriptions. The testing period was set at 10 weeks. In the NC group, there was a significant lowering of P levels from 5.86 +/- 1.31mg/dL before pulverization of the LC chewable preparation (week 0) to 5.38 +/- 1.26mg/dL after 2 weeks of administration of the pulverized medication (P=0.0310), 5.20 +/- 1.25mg/dL after 4 weeks (P=0.0077), and 5.12 +/- 1.34mg/dL after 6 weeks (P=0.0167). P levels in other patients than NC group showed no significant change. In this study, the P levels in the NC group was lowered significantly by changing the LC chewable to the pulverized prescription, and the residual LC images on the abdominal X-rays disappeared to the point where they could barely be confirmed.
引用
收藏
页码:54 / 59
页数:6
相关论文
共 50 条
  • [1] Questionnaire Survey and Serum Phosphorus Levels in Maintenance Hemodialysis Patients Switching Lanthanum Carbonate Formulation From Chewable Tablets to Granules
    Mukai, Itsumi
    Yoshizawa, Taku
    Kumagai, Junko
    Takahashi, Naoko
    Tsuchiya, Shinichiro
    THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 : 28 - 33
  • [2] RAPID REDUCTION OF SERUM PHOSPHORUS LEVELS BY LANTHANUM CARBONATE IN PATIENTS ON DIALYSIS
    Wilson, Rosamund
    Confer, Scharmen
    Pratt, Raymond
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A112 - A112
  • [3] Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis
    Finn, WF
    Joy, MS
    Hladik, G
    CLINICAL NEPHROLOGY, 2004, 62 (03) : 193 - 201
  • [4] Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study
    Sprague, S. M.
    Ross, E. A.
    Nath, S. D.
    Zhang, P.
    Pratt, R. D.
    Krause, R.
    CLINICAL NEPHROLOGY, 2009, 72 (04) : 252 - 258
  • [5] Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients
    Sakurada, Tsutomu
    Oishi, Daisuke
    Shibagaki, Yugo
    Yasuda, Takashi
    Kimura, Kenjiro
    HEMODIALYSIS INTERNATIONAL, 2013, 17 : S2 - S6
  • [6] Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy
    Matsunaga, C.
    Izumi, S.
    Furukubo, T.
    Satoh, M.
    Yamakawa, T.
    Uchida, T.
    Kadowaki, D.
    Hirata, S.
    CLINICAL NEPHROLOGY, 2007, 68 (02) : 93 - 98
  • [7] Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis
    Shigematsu, Takashi
    Sakai, Takehiko
    Iwasaki, Masashi
    Nagakura, Kazutake
    Murakami, Koichi
    Kono, Takashi
    Ando, Ken
    Kimura, Yasuo
    Sato, Junichi
    Tsuruta, Yoshinari
    Obayashi, Takaaki
    Kanashiro, Kana
    Seno, Hachiro
    Mori, Yasumitsu
    Murai, Hiroshi
    Nakao, Naoyuki
    Taki, Masafumi
    Arimoto, Katsuhiko
    Matsubara, Tatsuya
    Moriishi, Misaki
    Kawanishi, Hideki
    Watanabe, Hiroshi
    Minakuchi, Jun
    Kato, Takuma
    Hayashi, Ikuro
    Kaibara, Akihito
    Kawahara, Kazuhiko
    Nishida, Hayato
    Suzuki, Hiroko
    Takeda, Isao
    Kuwahara, Kazunori
    Sugita, Osamu
    Miyake, Susumu
    Noguchi, Tomonaga
    Yuasa, Kenji
    Ota, Kazumichi
    Terao, Naotami
    Sen, Yasukazu
    Iwasa, Yoshie
    Ishida, Mari
    Ishida, Yuji
    Nakao, Shoko
    Kobayashi, Takeshi
    Yachiku, Setsuko
    Komura, Chikashi
    Yao, Naoyuki
    Tsujimoto, Yoshihiro
    Tabata, Tsutomu
    Tahara, Hideki
    THERAPEUTIC APHERESIS AND DIALYSIS, 2008, 12 (01) : 55 - 61
  • [8] Lanthanum carbonate allows for a lower tablet burden to control serum phosphorus levels
    Vemuri, N
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A60 - A60
  • [9] LANTHANUM CARBONATE OFFERS SUSTAINED CONTROL OF SERUM PHOSPHORUS
    Smyth, Michael
    Poole, Lynne
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A104 - A104
  • [10] Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study
    Toida, Tatsunori
    Fukudome, Keiichi
    Fujimoto, Shouichi
    Yamada, Kazuhiro
    Sato, Yuji
    Chiyotanda, Susumu
    Kitamura, Kazuo
    CLINICAL NEPHROLOGY, 2012, 78 (03) : 216 - 223